2
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
5
Recurrence
3
Lymphoma
3
Glioblastoma
3
Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, B-Cell, Marginal Zone
2
Glioma
2
Brain Neoplasms
2
Solid Tumor
1
Pancreatic Neoplasms
1
Neoplasms, Plasma Cell
1
Melanoma
1
Leukemia
1
Gliosarcoma
1
Ependymoma
1
Disease Progression
1
Diffuse Intrinsic Pontine Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
9
Bevacizumab
8
toripalimab
7
senaparib
7
Fluorodeoxyglucose F18
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Fluorouracil
6
Gemcitabine
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Carboplatin
4
spartalizumab
3
sintilimab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
marizomib
×
Clear all
NCT04644107
2020-11-25
Expanded Access for Marizomib
Celgene
No longer available